PSIL: 1st Quarter 2023 Portfolio Review
Performance data quoted represents past performance and is no guarantee of future results. Current performance may be lower or higher than the performance data quoted. Investment return and principal value will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than original cost. Returns less than one year are not annualized. For the fund’s most recent standardized and month-end performance, please click www.advisorshares.com/etfs/psil.
Challenges continued this quarter for psychedelics stocks. Based on net asset value (NAV), PSIL was down -3.91% for Q1 2023.
During the quarter, new positions were added to Clearmind Medicine Inc. (CMND) and Core One Labs (CLABF) and Mindset Pharma (MSSTF) were removed from the portfolio.
Winners / Losers
FSD Pharma (HUGE) was up 96.60% for the quarter, Psybio Therapeutics Corp (PSYBF) was up 92.05% for the quarter, and Mind Medicine Mindmed Inc. (MNMD) gained 44.09% for the quarter. Clearmind Medicine Inc. (CMND) was down 63.61% and Greenbrook TMS Inc. (GBNH) was down 51.04% for the first quarter.
The psychedelic space continues to grow as they show promise as therapies for treatment-resistant depression and post-traumatic stress disorder.
We want to always remind people to think about how they want to invest in the psychedelic space as PSIL is designed to be fully or mostly fully invested. It is not a tactical strategy. If an investor wants to have a more aggressive risk managed approach to investing in this space, they should have a plan/strategy to trade around PSIL. Regardless of the type of investor you are, we appreciate your investment and trading of PSIL as we work to grow the ETF and raise awareness of this industry and its investment opportunities.
|Ticker||Security Description||Portfolio Weight %|
|CMPS||COMPASS PATHWAYS PLC||14.34%|
|HUGE||FSD PHARMA INC-CLASS B||7.24%|
|GHRS||GH RESEARCH PLC||6.13%|
|MNMD||MIND MEDICINE MINDMED INC||4.89%|
|ATAI||ATAI LIFE SCIENCES NV||4.80%|
|SEEL||SEELOS THERAPEUTICS INC||4.56%|
|SAGE||SAGE THERAPEUTICS INC||4.34%|
|ITCI||INTRA-CELLULAR THERAPIES INC||4.33%|
As of 03.31.2023. Cash is not included. Subject to change.
Please see our complete Fund holdings at advisorshares.com/etfs/psil. The holdings details are updated each market day.
To get updates on the funds, tune in to AdvisorShares’ AlphaNooner Show streaming live each regular weekday starting at 12:00 pm (East Coast time), where I am a guest almost every Tuesday. Other important guests from the psychedelics world often join too. Find it on most major social media platforms or visit our the AdvisorShares “Events” webpage for more information.